bms-986340
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 27, 2021 (NCT04895709)
Timeline
Indications
Studied for
- Bevacizumab · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Nivolumab · Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Standard of Care · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068454 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226856 | Phase 2 | Dec 1, 2025 | Mayo Clinic |
| NCT07011550 | Phase 2 | Nov 30, 2025 | University of Texas at Houston |
| NCT04895709 | Phase 1/Phase 2 (Phase 2) | May 27, 2021 | Bristol-Myers Squibb |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1